At ESMO Gastrointestinal Cancers Congress 2025 Jarle Bruun presented a poster entitled: Cytotoxicity of arfolitixorin versus leucovorin (LEU) with 5-fluorouracil (5FU) and oxaliplatin in colorectal cancer (CRC) patient-derived tumoroids (PDTs).
The conference took place between July 2nd and 5th in Barcelona, Spain. We are happy to present new data from this collaboration supporting further clinical development of Arfolitixorin. In this study, we show that Arfolitixorin has potent, concentration-dependent cytotoxic effects (both synergistic and additive), that enhances 5FU-oxaliplatin activity in CRC PDTs more effectively than leucovorin. Isofol Medical has published a video of Jarle Bruun providing additional details.
The work comes out of a collaboration with Akershus University Hospital and Institute for Molecular Medicine (Finland).